Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $28.00 price target on the stock.
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.